Circulating insulin-like growth factor-I and benign prostatic hyperplasia--a prospective study

Area of Science:

• Endocrinology
• Urology
• Molecular Biology

Background:

• Insulin-like growth factor-I (IGF-I) is a potent mitogenic and anti-apoptotic factor.
• IGF-I bioactivity is modulated by circulating levels, local production, and IGF-binding proteins (IGFBPs).
• IGFBPs influence IGF-I bioavailability and tissue availability.

Purpose of the Study:

• To investigate the potential role of IGF-I in the development of benign prostatic hyperplasia (BPH).
• To examine the relationship between IGF-I, IGFBP-1, IGFBP-3, and insulin levels and BPH risk.

Main Methods:

• A case-control study within the Northern Sweden Health and Disease Study.
• Identified 60 BPH cases (prostate resection history) and 120 controls.
• Measured plasma IGF-I, IGFBP-1, IGFBP-3, and insulin using immuno-radiometric assays from samples taken 3.2 years pre-surgery.

Main Results:

• Increased IGF-I levels, adjusted for IGFBP-3, showed a trend towards higher BPH risk (RR 2.16 for highest quartile).
• Elevated IGFBP-1 levels were associated with a decreased risk of BPH.
• The observed trends were not statistically significant (p(trend) = 0.10 for both).

Conclusions:

• Suggests that elevated IGF-I bioactivity might contribute to BPH development.
• Indicates a potential protective role for IGFBP-1 against BPH.
• Results are preliminary and necessitate confirmation in larger-scale studies.